Clinical Trial

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Name: Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy — clinical trial record (NCT07067268)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.

Trial Details

NCT Number	NCT07067268
Lead Sponsor	Fudan University
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	76 participants
Start Date	2024-09-14
Primary Completion	2026-09 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2025-07-16